Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges

F Teng, L Kong, X Meng, J Yang, J Yu - Cancer letters, 2015 - Elsevier
To date, several kinds of immunomodulating monoclonal antibodies (mAbs) have been
applied in clinical trials, such as anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) mAb …
被引用次数：101 相关文章

[引用][C] Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

F Teng, L Kong, X Meng, J Yang, J Yu - Cancer Letters, 2015 - cir.nii.ac.jp
Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements
and challenges | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

F Teng, L Kong, X Meng, J Yang, J Yu - Cancer Letters, 2015 - infona.pl
To date, several kinds of immunomodulating monoclonal antibodies (mAbs) have been
applied in clinical trials, such as anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) mAb …

Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.

F Teng, L Kong, X Meng, J Yang, J Yu - Cancer Letters, 2015 - europepmc.org
To date, several kinds of immunomodulating monoclonal antibodies (mAbs) have been
applied in clinical trials, such as anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) mAb …

Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

F Teng, L Kong, X Meng, J Yang, J Yu - Cancer letters, 2015 - pubmed.ncbi.nlm.nih.gov
To date, several kinds of immunomodulating monoclonal antibodies (mAbs) have been
applied in clinical trials, such as anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) mAb …

[引用][C] Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges

F Teng, L Kong, X Meng, J Yang, J Yu - Cancer Letters, 2015 - Elsevier Limited